3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
307
Recurrence
64
Neoplasms
32
Neoplasms, Plasma Cell
17
Lymphoma, Non-Hodgkin
14
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Vomiting
11
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Nausea
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Ovarian Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Hematologic Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Paraproteinemias
5
Lung Neoplasms
5
Leukemia
5
Small Cell Lung Carcinoma
4
Renal Insufficiency
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Plasmacytoma
4
Lymphoma, Follicular
4
Hematologic Diseases
4
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Interventions
enzalutamide
5
abiraterone
3
Prednisone
3
Docetaxel
3
Abiraterone Acetate
3
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-Resistant Prostate Cancer
×
Dexamethasone
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled